PHARMEXCEL LTDActive

Company number 06841897Private limited companyIncorporated 2009

Key figures

£971,565-28.1%
Net assets 2024/25
+17.9%
Average annual growth 2019/20–2024/25
01 m2 m3 m2019/202020/212021/222022/232023/242024/25

Like most small UK companies, PHARMEXCEL LTD does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
02 m4 m2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand906,4532,417,9512,598,1131,303,9911,127,155
Total assets1,414,1852,953,8733,333,3441,860,7471,688,936
Total liabilities929,5791,338,1991,175,181526,213731,923
Net assets / total equity495,8031,632,7342,176,1801,350,850971,565
Average number of employees132272717

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: PHARMEXCEL LTD

Company

PHARMEXCEL LTD is a private limited company registered with Companies House under company number 06841897. It was incorporated on 10 Mar 2009. Its status is active. The registered office is in Bedford (MK40). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Mar 2025); the company files small company accounts (filleted). Net assets were £971,565, down 28.1% on the previous year. Cash at bank and in hand was £1,127,155. Total assets were £1,688,936 and total liabilities £731,923. The company had an average of 17 employees. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 20 Aug 2027.